Learn about the most common types of Decentralized Clinical Trials (DCTs) and how to make their vast data sets actionable with secure, cloud-based data platforms....
Learn about the rules and principles of iRECIST, imaging endpoints, and special considerations for using iRECIST response criteria....
All members of our team have extensive knowledge and experience in imaging endpoint process standards of clinical trials. Our key players include expert project managers, imaging specialists, data management personnel, data quality evaluators, quality assurance staff, and adept software developers....
MERIT attended the WG-09: Ophthalmology meeting at AAO 2022. Read our article for several key takeaways. ...
MERIT’s webinar provides key takeaways that are important for oncology imaging clinical trials along with insights on how an Imaging Core Lab (ICL) can help you address imaging trial challenges. ...
Learn about the principles and recommendations of RANO response criteria for high grade glioma (HGG) and the imaging endpoint information that needs to be collected for clinical trials....
In this article, learn about the key role that IRCs play in imaging clinical trials....
Key takeaways from MERIT's Webinar: RECIST 1.1 and Oncology Trial Endpoints. ...
Imaging provides an unbiased, structural assessment of many disease states, which is a complement to functional outcome measures...
Globally, over 70,000 people are living with the often-debilitating effects of CF. While CFTR modulator treatments offer benefits for many, those with nonsense mutations require new therapies. ...
ETDRS BCVA is the primary endpoint for many, if not most, ophthalmic clinical trials. Learn about novel endpoints for visual function testing in this article. ...
Effective treatments for GBM remain a large unmet need in oncology. Developing an effective treatment is difficult due to many factors, including localization of tumors in the brain, resistance to therapy, migration of malignant cells into nearby brain tissue, and the blood-brain barrier. ...